Does CD123 provide a biological advantage to leukaemia stem cells?

CD123 是否为白血病干细胞提供生物学优势？

• 批准号: nhmrc : 1048071
• 负责人: A/Pr Paul Ekert
• 金额: $ 43.18万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/does-cd123-provide-stem-cells/111995
• 关键词: Does; CD123; provide; biological; advantage

Leukaemia is a devastating form of blood cancer affecting both young and old. We need to understand the diseased stem cell to eradicate this disease. Current therapy is poorly tolerated and the majority of patients ultimately die at relapse. We intend to investigate how we can make the cells more susceptible to therapy by understanding their biology.

白血病是一种毁灭性的血癌，对年轻人和老年人都有影响。我们需要了解患病的干细胞才能根除这种疾病。目前的治疗方法耐受性差，大多数患者最终死于复发。我们打算研究如何通过了解细胞的生物学来使其对治疗更敏感。